Compartmental Analysis of Drug Distribution

Principles of Clinical Pharmacology

Volumn , Issue , 2007, Pages 25-36

  Atkinson, Arthur J ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84862631841     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012369417-1/50043-2     Document Type: Chapter

References (29)

1. Atkinson AJ, Ruo TI, Frederiksen MC Physiological basis of multicompartmental models of drug distribution. Trends Pharmacol Sci. J Clin Invest 1991, 12:494.
2. Larsen PR, Atkinson AJ, Wellman HN, Goldsmith RE. The effect of diphenylhydantoin on thyroxine metabolism in man. J Clin Invest 1970, 49:159-181.
3. 2-urea kinetics in humans. Clin Pharmacol Ther 1993, 53:96-101.
4. Frederiksen MC, Ruo TI, Chow MJ, Atkinson AJ Theophylline pharmacokinetics in pregnancy. Clin Pharmacol Ther 1986, 40:1266-1279.
5. Øie S, Tozer TN. Effect of altered plasma protein bind-ing on apparent volume of distribution. J Pharm Sci 1979, 68:419-425.
6. oct: A tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds. J Med Chem 2001, 44:321-328.
7. Thummel KE, Shen DD Design and optimiza-tion of dosage regimens: Pharmacokinetic data. Goodman & Gilman's The pharmacological basis of therapeutics 2001, 1203-1205. McGraw-Hill, New York. 10th ed. H. JG, L. LE, G. AG (Eds.).
8. Lombardo F, Obach RS, Shalaeva MY, Gao F. Prediction of human volume of distribution values for neutal basic drugs. 2. Extended data set and leave-class-out statistics. J Med Chem 2004, 47:2490-2497.
9. Hager WD, Fenster P, Mayersohn M, Perrier D, Graves P, Marcus FI, Goldman S. Digoxin-quinidine interaction: Pharmacokinetic evaluation. N Engl J Med 1979, 300:1924-2023.
10. Sheiner LB, Rosenberg B, Marathe VV. Estimation of population characteristics of pharmacokinetic param-eters from routine clinical data. J Pharmacokinet Biopharm 1977, 5:1242-1250.
11. Piergies AA, Worwag EW, Atkinson AJ A concurrent audit of high digoxin plasma levels. Clin Pharmacol Ther 1994, 55:1238-1241.
12. Teorell T. Kinetics of distribution of substances administered to the body: I. The extravascular modes of administration. Arch Intern Pharmacodyn 1937, 57:445-479.
13. Sapirstein LA, Vidt DG, Mandel MJ, Hanusek G. Volumes of distribution and clearances of intra-venously injected creatinine in the dog. Am J Physiol 1955, 181:353-358.
14. Berman M. The formulation and testing of models. Ann NY Acad Sci 1963, 108:205-225.
15. Sedek GS, Ruo TI, Frederiksen MC, Frederiksen JW, Shih S-R, Atkinson AJ Splanchnic tissues are a major part of the rapid distribution spaces of inulin urea and theophylline. J Pharmacol Exp Ther 1989, 251:330-336.
16. Sherwin RS, Kramer KJ, Tobin JD, Insel PA, Liljenquist JE, Berman M, Andres R. A model of the kinetics of insulin in man. J Clin Invest 1974, 53:192-194.
17. Renkin EM. Effects of blood flow on diffusion kinet-ics in isolated perfused hindlegs of cats: A double circulation hypothesis. Am J Physiol 1953, 183:963-969.
18. Stec GP, Atkinson AJ Analysis of the contributions of permeability and flow to intercompartmental clearance. J Pharmacokinet Biopharm 1981, 9:1481-1492.
19. Dedrick RL, Flessner MF. Pharmacokinetic consider-ations on monoclonal antibodies. Prog Clin Biol Res 1989, 288:125-136.
20. Belknap SM, Nelson JE, Ruo TI, Frederiksen MC, Worwag EM, Shin S-G, Atkinson AJ Theophylline distribution kinetics analyzed by reference to simul-taneously injected urea and inulin. J Pharmacol Exp Ther 1987, 243:167-180.
21. Camarta SJ, Weil MH, Hanashiro PK, Shubin H. Cardiac arrest in the critically ill. I. A study of predisposing causes in 132 patients. Circulation 1971, 44:429-438.
22. Schentag JJ, Jusko WJ, Plaut ME, Cumbo TJ, Vance JW, Abrutyn E. Tissue persistence of gentamicin in man. JAMA 1977, 238:963-969.
23. Schentag JJ, Jusko WJ, Vance JW, Cumbo TJ, Abrutyn E, DeLattre M, Gerbracht LM. Gentamicin disposition and tissue accumulation on multiple dosing. J Pharmacokinet Biopharm 1977, 5:688-695.
24. Nagai J, Takano M. Molecular aspects of renal handling of aminoglycosides and strategies for preventing the nephrotoxicity. Drug Metab Pharmacokinet 2004, 19:327-329.
25. Reiner NE, Bloxham DD, Thompson WL. Nephrotoxicity of gentamicin and tobramycin given once daily or continuously in dogs. J Antimicrob Chemother 1978, 4(suppl A):559-577.
26. Verpooten GA, Giuliano RA, Verbist L, Eestermans G, De Broe ME. Once-daily dosing decreases renal accumulation of gentamicin and netilmicin. Clin Pharmacol Ther 1989, 45:159-179.
27. Colburn WA, Schentag JJ, Jusko WJ, Gibaldi M. A model for the prospective identification of the prenephrotoxic state during gentamicin therapy. J Pharmacokinet Biopharm 1978, 6:85-101.
28. Boxenbaum H, Battle M. Effective half-life in clinical pharmacology. J Clin Pharmacol 1995, 35:22-27.
29. Gibaldi M, Perrier D Pharmacokinetics 1982, 179-186, Marcel Dekker, New York. 2nd ed.